ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

Takeda seeks fast-track review of Moderna vaccine in Japan

Drug giant aims to supply doses for 20m people by June

A decision on Takeda's application for the Moderna vaccine will likely be made after results from a Japanese clinical trial are submitted.   © Reuters

TOKYO -- Takeda Pharmaceutical has asked the Japanese government to fast-track its application for Moderna's coronavirus vaccine, with plans to begin distribution by June.

Moderna is the third COVID-19 vaccine maker to undergo regulatory review in Japan, after Pfizer and AstraZeneca. Takeda is the one-stop agent for Moderna's vaccine here, handling clinical trials, application filing and distribution.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more